Vascular toxicity associated with anti-angiogenic drugs

KB Neves, AC Montezano, NN Lang… - Clinical Science, 2020 - portlandpress.com
Over the past two decades, the treatment of cancer has been revolutionised by the highly
successful introduction of novel molecular targeted therapies and immunotherapies …

Trial watch: dietary interventions for cancer therapy

S Lévesque, JG Pol, G Ferrere, L Galluzzi… - …, 2019 - Taylor & Francis
Dietary interventions have a profound impact on whole body metabolism, including
oncometabolism (the metabolic features allowing cancer cells to proliferate) and …

A comprehensive analysis of the glutathione peroxidase 8 (GPX8) in human cancer

Z Ren, Y He, Q Yang, J Guo, H Huang, B Li… - Frontiers in …, 2022 - frontiersin.org
Objective Nowadays, cancer is still a leading public health problem all over the world.
Several studies have reported the GPX8 could be correlated with the poor prognostic of …

Assessing treatment response and prognosis by serum and tissue metabolomics in breast cancer patients

J Debik, LR Euceda, S Lundgren… - Journal of proteome …, 2019 - ACS Publications
Patients with locally advanced breast cancer have a worse prognosis compared to patients
with localized tumors and require neoadjuvant treatment before surgery. The aim of this …

Circulating cytokines in metastatic breast cancer patients select different prognostic groups and patients who might benefit from treatment beyond progression

M Paccagnella, A Abbona, A Michelotti, E Geuna… - Vaccines, 2022 - mdpi.com
Cancer induces immune suppression to overcome its recognition and eradication by the
immune system. Cytokines are messengers able to modulate immune response or …

miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer

EM Lindholm, M Ragle Aure, MH Haugen… - Molecular …, 2019 - Wiley Online Library
One of the hallmarks of cancer is sustained angiogenesis. Favorable results have been
reported in some breast cancer (BC) patients receiving antiangiogenic therapy with …

Pro-inflammatory cytokines increase temporarily after adjuvant treatment for breast cancer in postmenopausal women: a longitudinal study

A Lindholm, ML Abrahamsen, K Buch-Larsen… - Breast Cancer …, 2024 - Springer
Background Breast cancer patients have an increased risk of cardiometabolic disease and
for many patients, adjuvant therapy causes an altered lipid profile, insulin resistance and …

Th2/Th17 cell associated cytokines found in seroma fluids after breast cancer surgery

N Pochert, M Schneider, MB Köpke, M Wild… - Archives of Gynecology …, 2023 - Springer
Purpose The development of a seroma after breast cancer surgery is a common
postoperative complication seen after simple mastectomy and axillary surgery. We could …

Bevacizumab-based chemotherapy triggers immunological effects in responding multi-treated recurrent ovarian cancer patients by favoring the recruitment of effector …

C Napoletano, I Ruscito, F Bellati, IG Zizzari… - Journal of clinical …, 2019 - mdpi.com
Increasing evidence strongly suggests that bevacizumab compound impacts the
immunological signature of cancer patients and normalizes tumor vasculature. This study …

Serum levels of inflammation‐related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers

ME Nome, LR Euceda, S Jabeen… - … journal of cancer, 2020 - Wiley Online Library
Angiogenesis is necessary for tumor growth and has been targeted in breast cancer;
however, it is unclear which patients will respond and benefit from antiangiogenic therapy …